What Is PT-141? Definition and What the Published Research Reports

Plain definition

PT-141 is the original laboratory code name for a synthetic peptide now known by the generic name bremelanotide. Unlike the erectile-dysfunction drugs most people have heard of, which widen blood vessels, PT-141 was designed to act in the brain: it binds to a family of receptors called melanocortin receptors that are involved in appetite, pigmentation, inflammation and sexual motivation. After roughly two decades of development, it was approved in the United States in 2019 as a prescription, self-administered subcutaneous injection for one narrow indication — acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women (PMID 31429064). The name "PT-141" persists in informal peptide discussion even though the regulated medicine is called bremelanotide.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question. Nothing here describes how the compound should be used.

What PT-141 is in biochemical terms

PT-141 is a cyclic heptapeptide analogue derived from α-melanocyte-stimulating hormone (α-MSH), a natural melanocortin. It is a metabolite of an earlier compound, melanotan II, and behaves as a non-selective agonist at melanocortin receptors, with activity at MC3R and MC4R considered most relevant to sexual behaviour. Early work described it as a melanocortin agonist investigated for sexual dysfunction and noted that its mechanism was central rather than vascular (PMID 12851303). Later reviews of the neurobiology described melanocortin signalling as acting on hypothalamic circuits that modulate excitatory and inhibitory inputs to sexual desire, which is why the agent was framed as a "central" rather than peripheral treatment (PMID 33455598).

Key identifiers used in the literature

Regulatory meaning of the term

The regulatory distinction matters for anyone reading the word "PT-141" online. Bremelanotide is an approved prescription product in the United States, first approved in 2019, and the approval review described it as an on-demand subcutaneous injection for premenopausal women with acquired, generalised HSDD (PMID 31429064). Pharmacy literature published after approval similarly characterised it as a new drug for HSDD and situated it alongside the only other approved agent for that condition (PMID 31893927). By contrast, material labelled "PT-141" in research-chemical channels is typically sold as research-use-only powder that has not been evaluated for identity, sterility or purity by any regulator. The two are not interchangeable descriptions, and the published clinical evidence applies to the approved formulation and the studied population, not to unregulated material.

How the term is used in peptide research — and where it is misused

In the scientific literature, "PT-141" appears mainly in older preclinical and phase 1/2 reports, while "bremelanotide" dominates later work. Preclinical publications described central nervous system effects on female sexual function in animal models, framing the peptide as a probe for melanocortin involvement in sexual motivation (PMID 17958619).

Common misuses of the term in non-scientific settings include:

• Treating it as an erectile-dysfunction drug equivalent. Early work explored sexual dysfunction broadly (PMID 12851303), but the trials that supported approval enrolled premenopausal women with HSDD (PMID 31599840). Extending conclusions to other populations goes beyond what those trials tested.
• Describing it as a general "libido peptide." The approved indication is a specific diagnosis — acquired, generalised HSDD — not low desire from any cause (PMID 36242769).
• Quoting effect sizes without context. Independent re-analyses argued that the average changes in trial outcome measures were small and that responder definitions influenced how impressive the results appeared (PMID 33678061).
• Confusing it with melanotan II. PT-141 is a related melanocortin peptide but a distinct compound with a different development history (PMID 12851303).

What the published literature reports

Preclinical work

An overview of preclinical CNS effects reported that bremelanotide acted on central pathways associated with female sexual function in animal models, supporting the hypothesis that melanocortin receptor activation modulated sexual motivation rather than peripheral blood flow (PMID 17958619). A later neurobiology review summarised the same theme for a clinical audience, describing hypothalamic melanocortin signalling as the proposed substrate for the observed behavioural effects (PMID 33455598).

Phase 3 trials

Two randomised, placebo-controlled phase 3 trials in premenopausal women with HSDD were published in 2019. The researchers reported that participants self-administered bremelanotide 1.75 mg subcutaneously as needed and that the study met its co-primary endpoints for change in desire and change in distress related to low desire compared with placebo (PMID 31599840). A companion publication reported on an open-label extension examining longer-term safety and efficacy, with the authors describing effects that were maintained over the extension period and a tolerability profile consistent with the core studies (PMID 31599847).

Interpretation and critique

Not all commentary agreed on the clinical meaningfulness of those results. A re-analysis of the phase 3 data argued that average benefits over placebo were modest relative to the outcome scales used and questioned the framing of HSDD as a disorder amenable to pharmacological correction (PMID 33678061). A subsequent article titled around "small effects, questionable outcomes" continued that critique, focusing on how endpoints were selected and reported (PMID 36809187). A separate narrative evaluation took a more neutral stance, reviewing efficacy, tolerability and the place of the injection among options for HSDD (PMID 36242769). A 2022 review in a neurology journal likewise summarised the evidence base for the indication (PMID 35076581). Readers encountering strong claims about PT-141 online are, in effect, encountering one side of an active academic disagreement.

Adverse Events: What Studies Report

A pooled analysis of safety across the clinical development programme reported that the most common treatment-emergent adverse events with bremelanotide were nausea, flushing and headache, that these were generally mild to moderate, and that nausea was a frequent reason participants discontinued (PMID 35147466). Transient increases in blood pressure and decreases in heart rate after dosing were described in the approval and review literature, which is why the product labelling addressed uncontrolled hypertension and cardiovascular disease (PMID 31429064). Reviews also noted focal hyperpigmentation as a reported event, consistent with melanocortin receptor activity in skin (PMID 31893927). These findings come from monitored clinical trials in a defined population and do not describe outcomes with unregulated material.

Related terms

• Bremelanotide — the generic name for the same molecule.
• Melanocortin receptor (MC1R–MC5R) — the receptor family targeted (PMID 33455598).
• α-MSH — the endogenous hormone the peptide analogue is modelled on.
• HSDD — the diagnosis used in the pivotal trials (PMID 31599840).
• On-demand dosing — a trial design term describing use as needed rather than daily.
• Research use only (RUO) — a labelling category meaning material is not intended for human administration.

Summary of the definition

PT-141 means bremelanotide: a melanocortin-receptor-agonist peptide, derived from α-MSH, first described as a candidate for sexual dysfunction in the early 2000s (PMID 12851303) and approved in 2019 for a single, narrowly defined indication (PMID 31429064). The published record contains both supportive trial reports and substantive critiques of effect size. Understanding the term therefore involves holding three things together: the biochemistry, the regulatory scope, and the ongoing debate about how much the measured effects mattered.

References

• Bremelanotide: First Approval (Drugs, 2019)
• Bremelanotide for Treatment of Female Hypoactive Sexual Desire (Neurology International, 2022)
• Safety Profile of Bremelanotide Across the Clinical Development Program (Journal of Women's Health, 2022)
• Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder (Journal of Sex Research, 2024)
• An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder (Expert Opinion on Pharmacotherapy, 2023)
• The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women (CNS Spectrums, 2022)
• Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women (Journal of Sex Research, 2021)
• Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder (Annals of Pharmacotherapy, 2020)
• Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (Obstetrics and Gynecology, 2019)
• PT-141: a melanocortin agonist for the treatment of sexual dysfunction (Annals of the New York Academy of Sciences, 2003)
• Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder (Obstetrics and Gynecology, 2019)
• Bremelanotide: an overview of preclinical CNS effects on female sexual function (Journal of Sexual Medicine, 2007)